RxDoctor Payments Data

Dustin Pagoria, MD

Urology · Stevens Point, WINPI 1427291236

Payments from drug & device makers

$2,655in general payments, 2019–2025

Across 77 payments — averaging $34.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Coloplast$385
  • Urogen Pharma, Inc.$360
  • Astellas Pharma US Inc$303
  • Johnson & Johnson$282
  • Boston Scientific$149
  • Merck$131
  • plus $1K from 23 others

What the payments were for

  • Food & beverage$2,58597%
  • Education$703%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,655 in reported general payments places this provider in the 70th percentile of 215 urology providers in Wisconsin.

See all urology providers in Wisconsin

Medicare billing

Part B allowed, 2024
$167,113
Medicare patients
352
Services billed
2,816

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide27$383,262
MyrbetriqMirabegron59$56,675
Tamsulosin Hcl353$3,866
Finasteride199$2,113
Methenamine Hippurate24$1,599
Oxybutynin Chloride ErOxybutynin Chloride102$1,146
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst65$1,047
Desmopressin Acetate14$1,013
Dutasteride24$812
Solifenacin Succinate15$541
Testosterone Cypionate11$398
Ciprofloxacin Hcl35$323
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim16$144
Oxybutynin Chloride11$119
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen23$98

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$303$439,93786 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 215 urology providers in Wisconsin.

Other urology in Stevens Point

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →